Nascent Biotech, Inc. (NBIO)
OTCMKTS · Delayed Price · Currency is USD
0.0077
0.00 (0.00%)
May 22, 2026, 4:00 PM EST
Nascent Biotech Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
51.85K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | 1.00M | 250.00K | 33.33% |
| Mar 31, 2021 | 750.00K | - | - |
| Mar 31, 2020 | - | - | - |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionNascent Biotech News
- 1 year ago - Nascent Biotech receives delinquency notification related to delayed filing - TheFly
- 1 year ago - Nascent Biotech recaps presentation at Emerging Growth Conference - TheFly
- 1 year ago - Nascent Biotech Presents at the July Emerging Growth Conference - Accesswire
- 2 years ago - Nascent Biotech embarks on fresh manufacturing run for pritumumab - TheFly
- 2 years ago - Nascent Prepares for Pivotal Phase II Research with Fresh Manufacturing Run - Accesswire
- 2 years ago - Nascent Biotech collaborates with HypoSpray on transdermal delivery system - TheFly
- 2 years ago - Nascent Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System - Accesswire
- 2 years ago - Nascent Biotech, Manhattan BioSolutions partner to explore pritumumab conjugates - TheFly